home / stock / ctdh / ctdh news

CTDH News and Press, Ctd Holdings Inc From 05/30/19

Stock Information
Company Name: Ctd Holdings Inc
Stock Symbol: CTDH
Market: OTC
Menu
CTDH CTDH Quote CTDH Short CTDH News CTDH Articles CTDH Message Board
Get CTDH Alerts

News, Short Squeeze, Breakout and More Instantly...
CTDH - CTD Holdings Announces $7.2 Million Private Placement

ALACHUA, FL / ACCESSWIRE / May 30, 2019 / CTD Holdings, Inc. (OTCQB: CTDH) (''CTD'' or the ''Company''), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announces a private placement to raise approximately...
CTDH - CTD Announces Home-Based Dosing of First Patient in US Extension Protocol of Clinical Trial using Intravenous Administration of Trappsol (R) Cyclo (TM) for Niemann-Pick Disease Type C

ALACHUA, FL / ACCESSWIRE / May 23, 2019 / CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced its first home-based infusion of its proprietary formulation of h...

CTDH - CTD Announces Participation and Support for Upcoming Gathering of Patient-Support Organizations for Niemann-Pick Disease type C

ALACHUA, FL / ACCESSWIRE / May 16, 2019 / CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that company representatives will attend and present at the 6th B...

CTDH - CTD Announces New Expanded Access Program in the United Kingdom using Trappsol(R) Cyclo(TM) Intravenously for Niemann-Pick Disease type C

Program is Open to One Patient Who Completed CTD's Clinical Trial with Trappsol ® Cyclo™ in the UK ALACHUA, FL / ACCESSWIRE / May 10, 2019 / CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment ...
CTDH - CTD Announces New Expanded Access Program in Taiwan using Trappsol Cyclo for Niemann-Pick Disease type C

Program is open to two patients who completed CTD's clinical trial with Trappsol ® Cyclo™ in the United States ALACHUA, FL / ACCESSWIRE / May 7, 2019 / CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the...

CTDH - CTD Holdings Announces M. Flint Beal, MD Joins Scientific Advisory Board

Expansion brings expertise on Alzheimer's Disease and other neurodegenerative diseases to the SAB ALACHUA, FL / ACCESSWIRE / April 15, 2019 / CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease w...

CTDH - CTD Holdings Announces Plan to Launch Clinical Trial of Trappsol (R) Cyclo (TM) in Alzheimer's Disease

ALACHUA, FL / ACCESSWIRE / March 14, 2019 / CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has initiated planning for a Phase I clinical ...
CTDH - CTD Holdings Announces Grant to U.S. Non-Profit Organization to Support Patient Participation in Informational Meetings with Regulators

Support is part of CTD’s efforts to recognize Rare Disease Day 2019 ALACHUA, Fla., Feb. 28, 2019 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet me...

CTDH - CTD Announces Appointment of Sharon H. Hrynkow, PhD as Chief Scientific Officer

ALACHUA, Fla., Feb. 15, 2019 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today the appointment of Sharon H. Hrynkow, PhD, the compa...

CTDH - CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo(TM) Provided Intravenously for Patients with Niemann-Pick Disease Type C

ALACHUA, Fla., Feb. 07, 2019 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, reports initial results from its two clinical trials using the compa...
Previous 10 Next 10